<DOC>
	<DOCNO>NCT00422513</DOCNO>
	<brief_summary>This 2 arm study compare 'time motion ' ( provider time spend anemia management ) effect hemoglobin ( Hb ) level , methoxy polyethylene glycol-epoetin beta ( Mircera ) epoetin alfa , anemic patient chronic kidney disease ( CKD ) hemodialysis . Patients stable intravenous ( iv ) epoetin alfa randomize either receive standard care therapy ( epoetin alfa ( iv ) 3 time weekly ) , receive Mircera 120-360 microgram ( iv ) , monthly . After titration period , average time spent anemia treatment 3 month period evaluate . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Comparing Mircera Epoetin Alfa Treatment Anemia Dialysis Patients With Chronic Kidney Disease .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; CKD ( stage V ) outpatient hemodialysis therapy &gt; = 3 month ; CKDrelated anemia treat epoetin alfa iv 3x/week &gt; = 3 month ; average hemoglobin ( Hb ) 1012 g/dL last 3 month . fail renal transplant within 12 month prior screen ; poorly control hypertension ; previous treatment Mircera .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>